← Back to all trials
Active Not Recruiting
NCT07704801
CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer
Conditions: Metastatic Breast Cancer
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Enrollment: 300
Sponsor: Sohag University
Location: Sohag university hospital Sohag
Summary
This study is a retrospective review aimed at evaluating the real-world outcomes and clinical efficacy of CDK4/6 inhibitors (such as Palbociclib, Ribociclib, or Abemaciclib) in patients diagnosed with metastatic luminal A and luminal B breast cancer. The study will assess how patients responded to these treatments based on their specific breast cancer subtype (Luminal A vs. Luminal B) by reviewing their medical records.
Eligibility Criteria
Inclusion Criteria:
* patients who are more than 18 years old at time of diagnosis and less than 80 years
* metastatic breast cancer luminal A and luminal B of either sex
Exclusion Criteria:
* patients diagnosed with double malignancy
* patients with incomplete medical records
* patients with organ failure
Source: ClinicalTrials.gov (NCT07704801). StuddyBuddy aggregates publicly available trial information.
